Recognized in a short span of time for collaborative and cost-effective research in the international arena Syngene and Clinigene are often referred as pioneers of the Indian custom and clinical services industry.
These subsidiary duo of the Bangalore-based biotech major Biocon contributed not less than 13% to operating revenues as the parent company saw revenues from Research Services grew 52% to Rs. 100 crore in FY 2006 from Rs. 66 crore.
While Syngene is setting up a new GMP level pilot facilities for both mammalian and microbial production up to phase I and early phase II, Clinigene International will move to a state-of-the-art new 60,000 square ft facility that is being established at the Biocon Park, at the Electronics City , Bangalore.
"The new lab for Syngene is in addition to our already existing cGMP grade chemical plant which supplies advanced intermediates and final products for preclinical use. The CBM plant will augment Syngene's ability to become a full-service provider to its clients. The new facility for Clinigene will enable it to expand its current operations," informed Kiran Mazumdar-Shaw, chairman and managing director, Biocon Limited.
Syngene is entering a new phase in drug discovery with the introduction of novel technologies and advanced, knowledge-driven service concepts. The subsidiary is today one of India's leading custom research service providers. Its state-of-the-art infrastructure and service offerings, enable it to participate in the drug development process, from discovery to supply of development compounds. With an increasing number of biologically-derived molecules being approved, demand for contract bio-manufacturing (CBM) is expected to rapidly grow over the next few years.
In the area of clinical research, Clinigene's ability to attract scientific talent, institute world-class facilities and maintain global ethical and regulatory standards, has made it "a partner of choice" for global pharma and biotech companies in conducting trials.
The demand for outsourced clinical research continues to grow exponentially and Clinigene will extend its operations to a 60,000 sq ft state-of-the-art facility by the first quarter of 2006. To augment our proven capabilities in conducting internationally benchmarked clinical trials for multinational pharma companies, the scaled-up establishment will have a new unit for phase I trials and also offer world-class Biometrics & Data Management Services, said Shaw.
Clinigene's Clinical Lab continues to conduct dedicated clinical trials, research/cohort studies and offers comprehensive laboratory services. We are the first lab in India to be accredited by CAP (College of American Pathologists) and NABL (National Accreditation Board for Testing and Calibration Laboratories). Endorsing the capabilities of our services, a leading global generic company will now be using the lab as their central laboratory.